Insilico Medicine Inc. is considering an initial public offering after securing funding at a valuation of more than $1 billion, reflecting growing interest in the potential use of AI to discover ground-breaking new drugs. US-based Insilico, which has extensive operations in China, secured $110 million in a financing round led by Value Partners Group. Existing backers including Warburg Pincus, US biotech investor OrbiMed Advisors Llc and the venture arm of Eli Lilly & Co. participated, the compan...